Home > Boards > US Listed > Biotechs > Contrafect Corp (CFRX)

I am buying today seems a good price

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Blutribe Member Profile
 
Followed By 74
Posts 3,997
Boards Moderated 0
Alias Born 08/09/04
160x600 placeholder
ContraFect Partners with Leading Orthopedic Center in Europe to Provide Compassionate Use of Exebacase to Patients with Chron... GlobeNewswire Inc. - 1/13/2020 8:00:10 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 1/10/2020 12:53:39 PM
ContraFect Announces First Patient Dosed in Pivotal Phase 3 DISRUPT Study of Exebacase as a Treatment for Staph aureus Bacter... GlobeNewswire Inc. - 1/10/2020 7:00:10 AM
ContraFect to Present at Biotech Showcase 2020 GlobeNewswire Inc. - 1/6/2020 5:30:10 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 1/6/2020 5:01:40 PM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 12/27/2019 5:29:53 PM
ContraFect Announces Initiation of Pivotal Phase 3 DISRUPT Study of Exebacase as a treatment for Staph aureus Bacteremia, Inc... GlobeNewswire Inc. - 12/20/2019 8:00:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/19/2019 4:18:54 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 12/18/2019 4:04:03 PM
ContraFect Announces First Gram-negative Product Candidate CF-370, a Direct Lytic Agent Targeting Pseudomonas aeruginosa GlobeNewswire Inc. - 12/18/2019 7:00:10 AM
ContraFect Corporation Prices Approximately $10 Million Public Offering of Common Stock GlobeNewswire Inc. - 12/17/2019 9:25:10 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 12/16/2019 4:36:58 PM
NexImmune Appoints Sol Barer as Chairman of the Board of Directors GlobeNewswire Inc. - 12/16/2019 7:30:10 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/16/2019 6:36:12 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/16/2019 6:32:13 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/16/2019 6:27:52 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/12/2019 5:04:44 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 12/11/2019 4:37:03 PM
Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp) Edgar (US Regulatory) - 12/10/2019 4:44:42 PM
ContraFect Corporation Prices Approximately $10 Million Public Offering of Common Stock and Concurrent $3 Million Private Pl... GlobeNewswire Inc. - 12/10/2019 8:46:39 AM
Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp) Edgar (US Regulatory) - 12/9/2019 5:19:05 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 12/9/2019 5:16:39 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/9/2019 5:08:26 PM
ContraFect Corporation Announces Proposed Public Offering of Common Stock and Concurrent Private Placement of Common Stock to... GlobeNewswire Inc. - 12/9/2019 4:03:10 PM
ContraFect to Present at the Piper Jaffray 31st Annual Healthcare Conference GlobeNewswire Inc. - 11/29/2019 9:00:10 AM
Blutribe   Monday, 02/11/19 11:26:55 AM
Re: Sugarplum post# 96
Post # of 200 
I am buying today seems a good price and value given the recent pullback and news...


YONKERS, N.Y., Jan. 17, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced that the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) has awarded the Company $2.3 million in additional funding over the course of the next two years. The Company will use the grant for the development of lysin therapeutics to treat serious, potentially life-threatening invasive infections caused by antibiotic-resistant Pseudomonas aeruginosa (P. aeruginosa), a virulent Gram-negative pathogen. This is an increase to the original CARB-X option amount of $1.0 million, part of the Company’s grant from CARB-X in March of 2017.

“We are pleased to have been awarded this additional funding from CARB-X. This follows our recent announcement of positive topline data from the Phase 2 trial of our lead lysin candidate exebacase, or CF-301, for the treatment of Staph aureus bacteremia, including endocarditis, which establishes clinical proof of concept for lysins as therapeutic agents. P. aeruginosa is a major cause of morbidity and mortality, often related to hospital acquired pneumonia, and is a major medical challenge, particularly for patients with cystic fibrosis. We look forward to advancing this program into the clinic as rapidly as possible,” said Cara Casino, M.D., Executive Vice President of Research & Development and Chief Medical Officer of ContraFect.

“We view this additional funding from CARB-X as continued validation of our novel lysin platform, which underscores the opportunity to combat highly resistant Gram-negative pathogens, considered to be the greatest threats to global health by both the CDC and WHO, with our proprietary lysin candidates.” said Steven C. Gilman, Ph.D., Chairman and Chief Executive Officer of ContraFect.

About CARB-X:

CARB-X is the world's largest public-private partnership devoted to antibacterial preclinical R&D. Funded by BARDA, Wellcome Trust, and NIAID, it will spend $450 million from 2017-2021 to support innovative products moving towards human clinical trials. CARB-X focuses on high priority drug-resistant bacteria, especially Gram-negative organisms. CARB-X is a charitable global public-private partnership led by Boston University School of Law. Other partners include the Broad Institute of Harvard and MIT, MassBio, the California Life Sciences Institute and RTI International. For more information, please visit www.carb-x.org and follow them on Twitter @CARB-X.

Buy OVERSOLD, sell OVERBOUGHT...Deep Pockets, so when I begin buying, watch out above! TECHNICAL and FUNDAMENTAL trader..
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist